Add Yahoo as a preferred source to see more of our stories on Google. As SARS-CoV-2 has become endemic At IDWeek 2025, (the joint annual meeting of the Infectious Diseases Society of America, the ...

A large observational study using US healthcare claims and electronic health record data suggests that Moderna’s updated 2024 ...

CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new ...

CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, Chief Executive Officer of ...

In an observational study involving nearly 440,000 veterans, both the BNT162b2 vaccine and the mRNA-1273 vaccine were highly effective at preventing infection, hospitalization, and death from Covid-19 ...

While mRNA vaccines against COVID-19 have been found to be safe and effective for the general population, in-depth evidence about safety and effectiveness for older adults and individuals with chronic ...

At least 87 times in the last few months, a health care provider has given a young child the wrong dose of COVID-19 vaccine. COVID mRNA vaccines are associated with a decreased risk of death in ...

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged ...

CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against ...